Fluorotechnics Expands Global Capability via Acquisition of ETC Elektrophorese-Technik
News Nov 14, 2007
Fluorotechnics has announced the acquisition of ETC Elektrophorese-Technik. Under the terms of the acquisition, Fluorotechnics will acquire all issued shares in ETC Elektrophorese-Technik in exchange for Fluorotechnics shares.
ETC Elektrophorese-Technik develops and manufactures high-end electrophoresis consumables and equipment used for diagnostics, quality control and species identification. Fluorotechnics is a developer and manufacturer of fluorescent research tools that are used in proteomics, cell biology and biochemistry.
Fluorotechnics CEO, Duncan Veal, states,” We are very excited by the synergies that the combination of the two companies will bring. This acquisition will allow us to cross-sell products to existing customers and to address new markets utilizing our joint expertise. Our ever-expanding sales and marketing team and enormous potential for our product offering means that we are well positioned for strong growth.”
Hanspeter Schickle, CEO of ETC, said,” We know that our customers will welcome the extended offering and complete solution that the range of Fluorotechnics and ETC products will now provide. The merged group possesses exceptional expertise, has a dynamic product pipeline and is set to become a leading supplier to life-scientists, globally.”
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.